Coya Therapeutics (COYA) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Coya Therapeutics (COYA) over the past year, losing 19.3% versus a loss of 20.9%. NRX Pharmaceuticals is the larger company by market cap ($123.0 million vs $116.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | NRXP |
|---|---|---|
| Share price | $4.96 | $2.84 |
| Market cap | $116.35M | $122.96M |
| 1-day change | -0.60% | -1.73% |
| YTD return | -13.97% | +6.64% |
| 1-year return | -20.92% | -19.27% |
| 5-year return | — | -97.18% |
| EPS (TTM) | $-1.07 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $5.06 |
| 52-week low | $3.71 | $1.62 |
| Distance from 52-week high | -36.00% | -43.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +206.65% | +1255.63% |
| Average volume | 158.05K | 865.49K |
| Shares outstanding | 23.46M | 43.30M |
| Employees | 8 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
COYA vs NRXP FAQ
Which is bigger, Coya Therapeutics or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $122.96M compared with $116.35M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or NRXP?
NRXP returned -19.27% over the past 12 months, compared with -20.92% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.